Growth Metrics

Emergent BioSolutions (EBS) EBT Margin (2016 - 2026)

Emergent BioSolutions has reported EBT Margin over the past 16 years, most recently at 8.58% for Q1 2026.

  • For Q1 2026, EBT Margin fell 3313.0% year-over-year to 8.58%; the TTM value through Mar 2026 reached 0.52%, up 871.0%, while the annual FY2025 figure was 11.15%, 2484.0% up from the prior year.
  • EBT Margin for Q1 2026 was 8.58% at Emergent BioSolutions, up from 34.1% in the prior quarter.
  • Over five years, EBT Margin peaked at 48.47% in Q3 2024 and troughed at 539.6% in Q2 2024.
  • A 5-year average of 49.64% and a median of 18.59% in 2022 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: crashed -46555bps in 2024 and later skyrocketed 52768bps in 2025.
  • Year by year, EBT Margin stood at 18.59% in 2022, then decreased by -6bps to 19.7% in 2023, then rose by 28bps to 14.18% in 2024, then crashed by -141bps to 34.1% in 2025, then surged by 125bps to 8.58% in 2026.
  • Business Quant data shows EBT Margin for EBS at 8.58% in Q1 2026, 34.1% in Q4 2025, and 24.92% in Q3 2025.